Adding tucatinib to trastuzumab and capecitabine is associated with improved progression-free and overall survival among heavily pretreated patients with ...
Clinical Phase Biopharmaceuticals company Cascadian Therapeutics today announced a review of recent advances in tucatinib, an investigational oral small molecule kinase inhibitor